Welcome to Phoenix Rising!
Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.
To become a member, simply click the Register button at the top right.
alex3619 wrote: The first comment made me chuckle. Anyone read the PACE study? I am not even sure I consider it valid science, there are so many glaring errors that have been ignored, as I and many others have discussed elsewhere.
Don't forget the erroneous and sloppy editorial by Bleijenberg & Knoop which they were asked to write!
Gee, it seems that campaigns of attack from extremists is the problem du jour for some psychiatrists, especially those who are working to expand the purview of psychiatry. Or maybe there's an outbreak of paranoia in the field, a kind of mass hysteria.
Conclusions
Melatonin analogues provide a new and efficacious mechanism for producing notable phase shifts in human beings. Although these drugs have been mainly studied for sleep disorders, they also have the potential to be used as primary or adjunctive drugs across a wider range of neuropsychiatric disorders characterised by persistent circadian disturbance. Importantly, only agomelatine (which also binds 5-HT2C receptors) has been reported to have clinically significant antidepressant effects. Because of its favourable adverse effect and safety profile, and the potential to help to restore circadian function between depressive episodes, this drug might occupy a unique place in the management of some patients with severe depression and other major mood disorders.
If Richard Horton was forced to resign, it probably wouldn't be the worst thing for the ME/CFS patient community.
Or maybe there's an outbreak of paranoia in the field, a kind of mass hysteria.